Naproxen Dosing for Juvenile Idiopathic Arthritis

Evidence-Based Dosing Recommendations

• Naproxen is the preferred NSAID for children with JIA due to its established efficacy and safety profile, as recommended by the American Academy of Pediatrics and supported by evidence from The Lancet Child and Adolescent Health 1, 2, 3
• Naproxen should be used as adjuvant therapy for pain and inflammation in children with JIA, not as monotherapy, with an adequate trial period of at least 8 weeks, as suggested by the American College of Rheumatology 1, 4

Treatment Algorithm

• An adequate trial of at least 8 weeks of naproxen therapy is recommended, as supported by The Lancet Child and Adolescent Health 1
• Methotrexate should be initiated as first-line disease-modifying therapy without delay, as NSAIDs alone are insufficient for disease control, according to the American College of Rheumatology 1, 4

Important Clinical Pearls

• Naproxen should not delay the introduction of disease-modifying antirheumatic drugs (DMARDs) like methotrexate, which is the cornerstone of JIA treatment, as recommended by the American Academy of Pediatrics and the American College of Rheumatology 1, 4
• Acetylsalicylic acid (aspirin) is not recommended for children with JIA due to safety concerns and risk of Reye's syndrome, as advised by The Lancet Child and Adolescent Health 1